Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs
- 109 Downloads
Intravenous enzyme replacement therapy with recombinant human α-l-iduronidase (rhIDU) is used weekly to treat mucopolysaccharidosis (MPS) I. We tested continuous administration of rhIDU at two dosing levels (0.58 mg/kg per week and 2 mg/kg per week) in MPS I dogs, and compared the efficacy of continuous infusion with the clinically used 0.58 mg/kg weekly three-hour infusion. Peak plasma concentrations of rhIDU were much higher in weekly-treated dogs (mean 256 units/ml) than steady-state concentrations in dogs treated with continuous infusion (mean 1.97 units/ml at 0.58 mg/kg per week; 8.44 units/ml at 2 mg/kg per week). Dogs receiving continuous IV rhIDU, even at a higher (2 mg/kg per week) dose, had consistently lower iduronidase levels in tissues than dogs receiving a weekly (0.58 mg/kg per week) dose. GAG storage was also less improved by continuous intravenous infusion. Adverse events were similar in all dosing groups. We found that continuous administration of 2 mg/kg per week rhIDU to MPS I dogs was insufficient to achieve GAG storage reduction comparable to 0.58 mg/kg weekly dosing.
KeywordsContinuous Infusion Enzyme Replacement Therapy Fabry Disease Disease Gauche Weekly Dose
enzyme replacement therapy
recombinant human α-l-iduronidase
Funding was provided by the Ryan Foundation for MPS Children and BioMarin Pharmaceutical Inc. Thanks to Michael McEntee, Rita Esquivel, and Dan Garner for their technical assistance. Thanks to Paul Fu, Sr, for measurement of urinary creatinine.
- Harmatz P, Kramer WG, Hopwood JJ, et al (2005) Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): a phase I/II study. Acta Paediatr Suppl 94: 61–68. doi: 10.1080/08035320510028139 PubMedCrossRefGoogle Scholar
- Wraith JE, Beck M, Lane R, et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human α-liduronidase (laronidase). Pediatrics 120: e37–e46. doi: 10.1542/peds.2006-2156 PubMedCrossRefGoogle Scholar